GlassScriptPhysician profile
Raymond E Kwa
NPI 1609853092
$1,896.44
in general payments reported to CMS, 2019-2025
10 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $159 · 2021: $322 · 2022: $235 · 2023: $361 · 2024: $277 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $967.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $482.86 | 2019-2024 | Xarelto |
| Abbvie INC. | $440.46 | 2021-2025 | |
| Inari Medical, INC. | $229.09 | 2021 | |
| Merck Sharp & Dohme LLC | $214.56 | 2019-2025 | Zerbaxa, Recarbrio |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $185.07 | 2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.36 | 2020-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $122.27 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $44.13 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $14.71 | 2020 | |
| Boston Scientific Corporation | $12.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Kwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.